Events | 2010.03.10
Diamyd Medical: Diamyd US Phase III Study Well under Way
STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Diamyd Medical (STO:DIAMB)(Pink Sheets:DMYDY) announces today that one hundred study participants have been included in the ongoing US Phase III study, DiaPrevent. The global Phase III program with the company’s lead drug candidate Diamyd® has thereby enrolled more than 430 children newly diagnosed with type 1 diabetes in Europe and the USA. One hundred patients are now enrolled in the company’s US Phase III study called DiaPrevent at
For more information, please visit
http://www.businesswire.com/news/home/20100309007292/en
Follow us on
